Bill
HB 5049
Expands school epinephrine provisions to include all epinephrine delivery systems, requires trained staff, stocking, and protocols for administration and reporting.
Status: Referred to second reading (reported with recommendation without amendment 11/05/2025)
Introduced by: Rep. Regina Weiss (primary sponsor); co-sponsors include Reps. DeBoer, Snyder, Pavlov, Xiong, Foreman, Tsernoglou, BeGole, Schmaltz, Kuhn, Frisbie, Jenkins‑Arno, Meerman, Bierlein, B. Carter, Hoskins, Bohnak, Prestin, St. Germaine, and Tisdel. Filed 3/13/2025; formally introduced 9/24/2025. Companion: SB 2118. Tie‑bar: HBs 5050–5054 (all must be enacted for any to take effect).
Purpose
- Update the Revised School Code (MCL 380.1179a) to broaden which epinephrine products may be stocked and administered in schools by replacing the term “epinephrine auto‑injector” with the broader statutory term “epinephrine delivery system.”
Key provisions
- Definition linkage: “Epinephrine delivery system” is defined in the Public Health Code (see companion HB 5050) to include, but not be limited to, epinephrine auto‑injectors, epinephrine inhalers, and epinephrine nasal sprays.
- Trained staff requirement: In each school with at least 10 instructional/administrative staff, the school board must ensure at least 2 employees are trained in the appropriate use and administration of an epinephrine delivery system. In schools with fewer than 10 such staff, at least 1 employee must be trained. Training must be conducted under the supervision of and include evaluation by a licensed registered professional nurse.
- Stocking and administration policies: Each school must have policies (consistent with department medication administration guidelines) providing for possession of at least 2 epinephrine delivery systems per school. Policies must authorize licensed/contracted registered nurses or trained school employees to:
- Administer a delivery system to a pupil with a prescription on file; and
- Administer a delivery system to any individual on school grounds believed to be having an anaphylactic reaction.
- Require parental/legal guardian notification if a pupil receives epinephrine.
- Department guidance and stakeholders: The Department of Education, with DHHS and input from multiple health and school‑nurse organizations, must revise medication administration guidelines (including stocking junior/regular dose systems and storage).
- Reporting and funding: Schools must annually report to the department instances of administration (total administrations, number of pupils not previously known to be severely allergic, number using school stock). School boards should seek nonstate funding; if unable, they may apply to the department for reimbursement (legislative appropriation required). The department will report annually to the Legislature on reimbursement applications and outcomes.
Who is affected
- Public school districts, intermediate school districts, public school academies, school nurses, trained school employees, students (including visitors/other individuals on school grounds), and, via companion bills, childcare providers, law enforcement/firefighter programs, and regulatory references in the Public Health Code.
Fiscal impact
- House Fiscal Agency analysis: No fiscal impact on the state, local school districts/ISDs/PSAs, LARA, or the State Police. Reimbursement mechanism requires legislative appropriation if used.
Procedural/timing notes
- The bill amends MCL 380.1179a and will not take effect unless all tie‑bar bills (HBs 5050–5054) are enacted. Reported out of committee 11/05/2025 and placed on second reading.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
